简体
  • 简体中文
  • 繁体中文
×

热门资讯> 正文

InMed Pharma收到纳斯达克不合规通知

2026-03-28 05:12

  • InMed Pharmaceuticals (INM) received a notice from Nasdaq for failing the $1 minimum bid price requirement.
  • The deficiency follows shares trading below $1.00 for 30 consecutive trading days (Feb 11–Mar 26, 2026).
  • The notice has no immediate impact, and shares will continue trading.
  • InMed has a 180-day period to regain compliance by achieving a $1.00+ closing price for 10 consecutive days.
  • The company may qualify for an additional 180-day extension if other listing criteria are met.
  • InMed may consider actions such as a reverse stock split to regain compliance.
  • Failure to meet requirements could lead to delisting, though the company has the right to appeal.

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
问答大全
（工作日09：30 - 次日05：30）
客户端：
关注我们：
  • 微信公众号二维码

© 2026 深圳市时代华盛网络科技有限公司版权所有 粤ICP备16068286号